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Abstract
This 48-week, randomized, placebo-controlled phase 3 study (DMD114044; NCT01254019) evaluated efficacy and safety of subcutaneous
drisapersen 6 mg/kg/week in 186 ambulant boys aged ≥5 years, with Duchenne muscular dystrophy (DMD) resulting from an exon 51 skipping
amenable mutation. Drisapersen was generally well tolerated, with injection-site reactions and renal events as most commonly reported adverse
events. A nonsignificant treatment difference (P = 0.415) in the change from baseline in six-minute walk distance (6MWD; primary efficacy
endpoint) of 10.3 meters in favor of drisapersen was observed at week 48. Key secondary efficacy endpoints (North Star Ambulatory Assessment,
4-stair climb ascent velocity, and 10-meter walk/run velocity) gave consistent findings. Lack of statistical significance was thought to be largely
due to greater data variability and subgroup heterogeneity. The increased standard deviation alone, due to less stringent inclusion/exclusion
criteria, reduced the statistical power from pre-specified 90% to actual 53%. Therefore, a post-hoc analysis was performed in 80 subjects with a
baseline 6MWD 300–400 meters and ability to rise from floor. A statistically significant improvement in 6MWD of 35.4 meters (P = 0.039) in
favor of drisapersen was observed in this subpopulation. Results suggest that drisapersen could have benefit in a less impaired population of DMD
subjects.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Keywords: Duchenne muscular dystrophy; Drisapersen; Dystrophin; Antisense oligonucleotide; Exon skipping; six-minute walking distance

1. Introduction
Duchenne muscular dystrophy (DMD, OMIM 310200) is a
rare neuromuscular disease, affecting one in 3500–5000
newborn boys [1–3] as reported from a number of screening
programs worldwide [4,5]. It is an X-linked recessive condition
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caused by mutations in the DMD gene, with deletions
flanking exon 51 most commonly observed [6]. This results
in disruption of the transcriptional open-reading frame and
leads to prematurely aborted dystrophin synthesis [7]. The
lack of functional dystrophin results in progressive damage
and degeneration of muscle fibers, followed by a predictable
clinical trajectory [8]. Initial development of motor skills
is followed by a plateau phase, after which progressive
muscle function deterioration with age is observed (decline to
be expected from 7 years of age) [9–15]. As a result, most
subjects become wheelchair-bound by their mid-teens [8].

https://doi.org/10.1016/j.nmd.2017.10.004
0960-8966/© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Subsequently, respiratory failure and cardiomyopathy emerge,
with most subjects developing nocturnal hypoventilation or
respiratory failure requiring non-invasive mechanical
ventilation or death before the age of 30 years [16]. DMD is
currently mainly managed by standard of care treatments such
as glucocorticoids [16,17], physiotherapy, management of
spine deformity, and cardiorespiratory dysfunction [8,18]. This
better clinical management has improved prognosis and life
expectancy over the last few decades [19,20]. Ataluren received
conditional approval in the European Union but can only be
used for treating DMD caused by a nonsense mutation
(nmDMD) in ambulatory boys aged ≥5 years [21,22].
Drisapersen is a 2′-O-methyl-phosphorothioate antisense
oligonucleotide (AON) that induces exon 51 skipping during
pre-messenger RNA splicing [23], generating a shorter in-frame
largely functional dystrophin protein [24]. This approach could
be used to treat approximately 13% of DMD subjects [6]. In a
comprehensive clinical development program, 2 randomized,
placebo-controlled, phase 2 studies (DMD114117 [25], and
DMD114876 [McDonald et al. Unpublished results]) examined
the effect of 6 mg/kg/week drisapersen in ambulant boys with
a six-minute walk distance (6MWD) of ≥75 meters and a rise
from floor (RFF) time of ≤7 seconds (except for 2 boys). Both
studies have provided evidence that continuous subcutaneous
(sc) drisapersen 6 mg/kg/week improved mean 6MWD versus
placebo after 24 weeks by 35 meters (P = 0.014) and 27 meters
(P = 0.069), respectively. This was maintained after 48 weeks
in DMD114117 (mean difference 36 meters, P = 0.051) [25].
The treatment benefit in the randomized, placebo-controlled,
phase 2 studies was supported by long-term phase 1/2 extension
data (~3.4 years) [26] compared with matched natural history
(NH) controls with a comparable observational time frame
[27].
The current phase 3 study (DEMAND III; DMD114044;
NCT01254019) evaluated the efficacy and safety of sc
drisapersen 6 mg/kg/week over 48 weeks in a larger cohort
(N = 186) of ambulant DMD subjects.
2. Subjects and methods
The CONSORT checklist is available as supporting
information.
2.1. Study population
The DMD114044 study was performed in accordance with
the International Conference on Harmonisation Good Clinical
Practice guidelines, the Declaration of Helsinki (2008), and
applicable country-specific requirements. Written informed
consents from parents/caregivers and assent (from appropriately
aged subjects) were obtained for all subjects prior to any study
procedure.
Ambulant boys aged ≥5 years, with DMD resulting from an
exon 51 skipping amenable mutation, were eligible for inclusion.
Inclusion criteria included: a life expectancy >1 year;
3 pre-treatment 6MWD tests ≥75 meters within 20% of each
other; glucocorticosteroid therapy for ≥6 months and stable

5

dose and regimen for ≥3 months prior to screening, with the
expectation of remaining on similar dose/regimen for the study
duration. Key exclusion criteria included: any additional missing
exon that could not be treated with exon 51 skipping; use of
concomitant medication (anticoagulants, antithrombotics,
antiplatelet agents, idebenone and other forms of coenzyme
Q10); any liver and renal impairment; and symptomatic
cardiomyopathy.
2.2. Study design and treatment
This randomized, double-blind, placebo-controlled, phase 3
study was conducted between December 30, 2010 and June 28,
2013 at 44 centers in 19 countries: Argentina, Belgium, Brazil,
Canada, Chile, Czech Republic, Denmark, France, Germany,
Italy, Japan, Korea, the Netherlands, Norway, Poland, Russian
Federation, Spain, Taiwan, and Turkey.
Following screening, eligible subjects were centrally
randomized by an interactive voice response system and a
random allocation sequence (without using any stratification
factors) in a 2:1 ratio to receive either sc drisapersen
6 mg/kg/week or volume-matched placebo for 48 weeks.
The study was fully blinded with respect to treatment
allocation. All treatments were prepared and administered by
trained and qualified unblinded personnel who were not
involved in the efficacy assessments. To minimize the risk of
injection-site reactions, rotation of the injection site on a
weekly basis was recommended.
2.3. Endpoints
The primary efficacy endpoint was change from baseline
6MWD at week 48 [9,28]. Key secondary efficacy endpoints
were the change from baseline in: North Star Ambulatory
Assessment (NSAA) [16,29], 4-stair climb ascent velocity, and
10-meter walk/run velocity. Other secondary efficacy endpoints
included: other timed-function tests (RFF time and 4-stair
climb descent velocity), muscle strength, pulmonary function,
molecular efficacy (exon 51 skipping at mRNA level and
dystrophin expression) [30,31], serum creatine kinase (CK),
and functional and health outcome assessments (Clinical
Global Impression of Improvement [CGI-I] [32], pediatric
quality of life [PedsQL] neuromuscular module [33], health
utility index [HUI], and activities of daily living).
Pharmacokinetic evaluations included the drisapersen
concentration in plasma and muscle tissue. Safety and
tolerability endpoints included adverse events (AEs), serious
AEs, local tolerability, laboratory parameters (including lactate
dehydrogenase [LDH], which was evaluated post-hoc), vital
signs, electrocardiograms, echocardiography, and physical
examination.
2.4. Assessments
The primary efficacy endpoint and most secondary efficacy
assessments were conducted at baseline, and subsequently
every 12 weeks or at early withdrawal. Site staff members were
trained on functional efficacy endpoints by highly experienced
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and well-trained physiotherapists, who provided refresher
training as required throughout the study.
The 6MWD was assessed as reported previously [9,28]. An
age- and height-based equation fitted to normative data by
Geiger et al. was applied to the 6MWD data and a percentpredicted 6MWD was calculated for each subject [34,35].
Timed-function test velocities for RFF, 4-stair ascent and
descent, and 10-meter walk/run were calculated as described by
McDonald et al. [36].
Muscle strength was evaluated by handheld myometry using
a microFET dynamometer (Biometrics BV, Almere, The
Netherlands), whereas pulmonary function was assessed using
a handheld Koko spirometer (PDS Instrumentation, Louisville,
KY, USA) and a magnehelic manometer (Dwyer Instrument,
Michigan City, IN, USA). Pulmonary function testing included
the following parameters: forced vital capacity (FVC) [37],
forced expiratory volume in 1 second (FEV1), peak expiratory
flow (PF), and peak cough flow (PCF) [38].
The CGI-I was a single-item question designed to provide a
brief, stand-alone assessment of the clinician’s view of the
subject’s global functioning (with 7 potential responses ranging
from “much improved” to “very much worse”) after initiating
study drug, compared to their global functioning just prior to
initiating treatment [32]. Health-related quality of life was
measured via the PedsQL, with total score ranging from 0–100
and higher scores indicating a better health-related quality of
life. The appropriate age-specific version of the PedsQL was
completed, with children aged ≤7 years completing a different
questionnaire than children aged >7 years [33]. The HUI is
comprised of a family of generic health profiles and preferencebased systems for the purposes of measuring health status,
reporting health-related quality of life, and producing utility
scores.
Blood samples for pharmacokinetic assessments were
collected pre-dose and between 1 to 4 hours post-dose, at week
8, 12, 24, or 36 (depending on which visit the muscle biopsy
was taken) and at week 47. At week 0, samples were collected
pre-dose and at 0.5, 1, and 3 hours post-dose.
AEs were coded using MedDRA System Organ Class and
Preferred Term.
2.5. Statistical methods
It was planned to randomize 180 subjects in order to recruit
at least 162 evaluable subjects. It was calculated that 162
evaluable subjects would provide 90% power to detect 30
meters difference of change from baseline in 6MWD between
drisapersen and placebo, assuming a common standard
deviation of 55 meters (using a two-group t-test with a 0.05
two-sided significance level). It is noteworthy that most subjects
included in DMD114117 study had a baseline 6MWD >300
meters and a smaller SD for the change in 6MWD after
drisapersen treatment [25].
2.5.1. Pre-specified analyses
The primary efficacy analysis of the change from baseline in
the 6MWD used the intent-to-treat (ITT) population to which a

mixed model for repeated measures (MMRM) was applied, that
included fixed terms for treatment, visit, treatment-by-visit
interaction, country grouping, baseline value, and baseline
value-by-visit interaction. The MMRM was used to assess
longitudinal data and allows to correct missing data.
If a statistically significant treatment difference (5% level)
is observed for the primary efficacy endpoint, the 3
aforementioned key secondary endpoints are tested in a sequential
manner, using the same methodology. For other secondary
efficacy endpoints, statistical comparisons were made and the
results were considered supportive.
Furthermore, pre-specified subgroup summary statistics of
the primary efficacy endpoint based on age (≤7 years; >7 years)
were performed.

2.5.2. Post-hoc analyses
In more recent years of DMD research, NH study outcomes
highlighted the importance of baseline characteristics, such as
age, 6MWD, and the ability to RFF, as prognostic factors for
loss of ambulation [9–15,39]. Subjects with a baseline 6MWD
of less than 300 meters and/or who are unable to perform the
RFF test at baseline are at greater risk of imminent loss of
ambulation than subjects with a baseline 6MWD of above 300
meters and/or who are able to perform the RFF test [10,13,14].
Subjects with a baseline 6MWD of above 400 meters are too
stable to detect a treatment difference in a study of one year
duration. In addition, a 6MWD <300 meters is associated with
a significant reduction in lower extremity fat fraction on
magnetic resonance imaging hence less muscle substrate is
present to effect a change in lower extremity ambulatory
endpoints [40]. Therefore, the same MMRM analysis was
performed in a subgroup of subjects with a baseline 6MWD
result between 300 and 400 meters and who were able to
RFF.
The pre-specified analysis for the CGI-I was only for the
dichotomized variable of subjects who improved much or very
much versus those who did not improve category. This analysis
was not carried out due to the small sample size in the very
much improved and much improved category for the placebo
group with the non-convergence of the statistical model.
Instead, an analysis of all 7 CGI-I categories using the
Cochrane-Mantel-Haenszel test with row mean score was
conducted. The Cochrane-Mantel-Haenszel test was selected as
controls were stratified and matched at baseline.
For all post-hoc analyses in this manuscript, nominal
P-values are reported without adjustment of multiplicity.
Statistical significance is defined as nominal P < 0.05,
which does not take into account the post-hoc nature of the
analyses.

3. Results
3.1. Study population
A total of 186 subjects were randomized by 44 centers in 19
countries to drisapersen 6 mg/kg/week (N = 125) or placebo
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Fig. 1. DMD114044 subject flow diagram.
a
Subjects could only have one primary reason for withdrawal.
b
The ITT population was defined as all subjects randomized to the study who received at least one dose of study medication and had at least one post-baseline efficacy
assessment.
c
All subjects who received at least one dose of study medication were included in the safety population.
d
The PK population was defined as all subjects who were randomized to the study and from whom at least one blood sample was obtained for assessment of
drisapersen levels.
e
The PP population was defined as all ITT subjects who had no major protocol deviations.
f
A subject could have more than one major protocol deviation.
6MWD = six-minute walk distance; ITT = intent-to-treat; PK = pharmacokinetic; PP = per-protocol.

(N = 61; Fig. 1). All subjects were included in the ITT
population. At baseline in both treatment arms (N = 186), the
age ranged from 5 to 16 years and the 6MWD from 107 to 566
meters. However, an imbalance in baseline disease severity
characteristics was observed between the 2 treatment arms
(Table 1), with a lower mean 6MWD and greater mean age
observed in the drisapersen than in the placebo group (337.5
versus 348.0 meters and 8.3 versus 8.0 years old, respectively).
Furthermore, 15.2% of subjects included in the drisapersen
group were unable to perform the RFF test at baseline

compared with 9.8% of subjects included in the placebo group.
This imbalance reflected the inclusion of an older and more
impaired population in the drisapersen group at baseline.
3.2. Efficacy
3.2.1. Primary endpoint
Over 48 weeks, 10% of the placebo group compared
with 12% of the drisapersen group lost ambulation. Of those
who lost ambulation, 5 of 6 placebo-treated subjects and 14
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Table 1
Baseline demographics and clinical characteristics (safety population).
Mean (SD)

Age, years
Height, cm
Weight, kg
Time since first symptoms, months*
Time since diagnosis, months
Time since first corticosteroid taken, months
6MWD, meters
RFF time, seconds†
% subjects unable to RFF

treatment benefit in 6MWD of 35.4 meters (95% CI: 1.8, 69.0)
in favor of drisapersen was observed (P = 0.039).

Drisapersen
6 mg/kg/week
(N = 125)

Placebo
(N = 61)

8.3 (2.4)
124.0 (10.8)
30.1 (10.3)
71.8 (31.6)
58.0 (35.2)
35.6 (29.0)
337.5 (95.6)
12.34 (14.98)
15.2%

8.0
122.0
26.9
66.77
54.2
29.1
348.0
13.41
9.8%

(2.4)
(9.6)
(7.6)
(31.3)
(32.8)
(25.8)
(92.2)
(15.88)

N = 122 for the drisapersen group and N = 58 for the placebo group.
N = 106 for the drisapersen group and N = 55 for the placebo group.
6MWD = six-minute walk distance; RFF = rise from floor; SD = standard
deviation.
*
†

Mean Change (SE) from Baseline 6MWD
(meters)

of 15 drisapersen-treated subjects had a baseline 6MWD
<300meters; 3 of 6 placebo and 9 of 15 drisapersen-treated
subjects were unable to RFF at baseline. A decrease in mean
change (standard error [SE]) from baseline 6MWD to week 48
was observed in the placebo (−52.7 [10.4] meters) as well as in
the drisapersen group (−42.3 [7.4] meters), with a mean (95%
confidence interval [95% CI]) treatment benefit of 10.3 (−14.7;
35.3) meters in favor of drisapersen (P = 0.415; Fig. 2).
A pre-specified MMRM subgroup analysis by age (≤7 years;
>7 years), showed a greater mean (95% CI) treatment
difference in change from baseline 6MWD over placebo for the
drisapersen treatment group in younger subjects (21.5 [−6.6,
49.6] meters; P = 0.131) than in older subjects (6.9 [-29.0, 42.9]
meters; P = 0.703) at week 48.
A post-hoc MMRM analysis was performed in a subgroup
of 83 subjects (52 drisapersen; 31 placebo) with a baseline
6MWD between 300 to 400 meters and a mean difference in
6MWD at week 48 of 27.8 meters (95% CI: −7.5, 63.1). Three
subjects in this subgroup were unable to perform the RFF test at
baseline; all belonged to the drisapersen group of whom 1 lost
ambulation at week 60 visit (12 week visit in the extension
study). Upon removal of these 3 subjects, a significant mean
0

0

3.2.2. Secondary efficacy endpoints
3.2.2.1. Ambulatory function endpoints. Using the prespecified statistical analysis model, no statistically significant
differences were observed for the secondary ambulatory
function efficacy endpoints: NSAA (P = 0.757), 4-stair climb
ascent velocity (P = 0.718), 4-stair climb descent velocity
(P = 0.513), 10-meter walk/run velocity (P = 0.881), percentpredicted 6MWD (P = 0.320), and time to RFF (P = 0.658;
Fig. 3A).
Similarly as for the primary efficacy endpoint, a post-hoc
analysis was performed in which the same MMRM analysis
was applied to the subgroup of 80 subjects (49 drisapersen; 31
placebo) with a baseline 6MWD result between 300 to 400
meters and who were able to RFF (Fig. 3B). As was the case for
the 6MWD, the mean difference in percent-predicted 6MWD
was in favor of drisapersen in this subpopulation. For the other
secondary efficacy endpoints, larger mean improvements
observed in NSAA, RFF velocity, 10-meter walk/run velocity,
and 4-stair descent velocity in the drisapersen versus the
placebo group were observed.
3.2.2.2. Other secondary endpoints. At week 48, 10% of
drisapersen-treated subjects compared to 2% of placebo-treated
subjects were considered responders (“much improved” or
“very much improved”) on the CGI-I scale. The pre-specified
inferential analysis of “(very) much improved” in CGI-I could
not be carried out due to the fact that only 1 placebo subject was
in the “much improved” category. Hence, a post-hoc analysis of
all CGI-I categories was performed, showing a statistically
significant difference in favor of drisapersen in the entire study
population (P = 0.002; Fig. 4), and in the subgroup of subjects
with a baseline 6MWD of 300–400 meters and able to RFF
(P = 0.001).
There were no clinically meaningful treatment differences
between drisapersen and placebo for the PedsQL neuromuscular
module, HUI assessments, and activities of daily living (data
not shown). In addition, no clinically meaningful treatment
difference was observed for any of the pulmonary function
tests (including FVC, FEV1, PF, and PCF).

-10
-20
-30

-42.32 *

-40
-50

-52.65

-60
-70

Baseline

Week 12

Week 24

Week 36

Week 48

Placebo, N

61

58

59

60

59

Drisapersen, N

125

124

122

116

117

Fig. 2. Pre-specified analysis of the mean change (SE) from baseline to week
48 in 6MWD (intent-to-treat population).
6MWD = six-minute walk distance: SE = standard error.
*P = 0.415.

3.2.2.3. Laboratory and biomarker assessments. At week 48,
the adjusted mean [SE] CK serum concentration declined
significantly in the drisapersen (−5273.5 [359.1] IU/L) versus
the placebo (−1228.5 [500.6] IU/L) group (P < 0.001). The
difference was statistically significant from week 12 onwards
(Fig. 5A). Similarly, the mean [SE] LDH serum concentration
also declined more in the drisapersen (−375.3 [21.40)] than in
the placebo (−119.2 [36.58] IU/L) group at week 48
(P < 0.001). Also this difference was statistically significant
from week 12 onwards (Fig. 5B).
3.2.2.4. Pharmacokinetic analysis. Blood samples for
pharmacokinetic analysis were taken using sparse sampling,
therefore no pharmacokinetic parameters were calculated using
non-compartmental analysis. The median trough drisapersen

N. Goemans et al. / Neuromuscular Disorders 28 (2018) 4–15
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Fig. 3. Forest plot of secondary ambulatory endpoints.
A) Pre-specified analysis in the intent-to-treat population.
B) Post-hoc analysis in a subpopulation with baseline 6MWD results between 300 and 400 meters and who were able to perform the RFF test.
6MWD = six-minute walk distance; RFF = rise from floor; NSAA = North Star Ambulatory Assessment; SD = standard deviation; CI = confidence interval.

plasma concentration increased over time up to 48 weeks of
dosing (Figure S2A), whereas the mean drisapersen muscle
tissue homogenate concentration slowly increased over time
reaching steady state at approximately 36 weeks post-treatment
(Figure S2B).
3.3. Safety
The majority of subjects reported at least one on-treatment
AE (98% drisapersen; 95% placebo), most of which were mild
to moderate in intensity (7% of drisapersen and 3% of placebo
subjects reported severe AEs; Table 2). Serious AEs were
reported in 10% of drisapersen-treated and 8% of placebotreated subjects, of which none were reported in more than
1 subject in either treatment group. Two (1.6%) subjects in
the drisapersen group had a drug-related serious AE that
led to study discontinuation (glomerulonephritis [N = 1] and
intracranial venous sinus thrombosis and spinal pain [N = 1]).
No deaths occurred during the study and no subjects withdrew
due to meeting pre-defined criteria for dose interruption.
AEs of special interest were reported in 91% of the
drisapersen-treated and 61% of the placebo-treated group. The

most commonly reported on-treatment AEs of special interest
were local injection-site and renal AEs.
Injection-site AEs occurred more frequently in the
drisapersen-treated (78%) than in the placebo-treated (16%)
group; with erythema (50%), discoloration (33%), reaction
(19%), pain (18%), induration (14%), and pruritus (14%) most
commonly reported in the drisapersen group. None were
reported as serious AEs and the majority of events (65% of all
events) was resolved or was being resolved over the
observational time frame or was resolved with sequelae (18%
of all events). AEs with an outcome of not resolved injectionsite reactions (16% of all events; followed-up from December
30, 2010 to March 17, 2014) were primarily injection-site
extravasation (2/2 events; 100%), lipodystrophy acquired (8/8
events; 100%), lipoatrophy (3/3 events; 100%) pigmentation
disorder (6/7 events; 86%), injection-site atrophy (9/13 events;
69%), injection-site reaction (40/106 events; 38%), injectionsite discoloration (64/230 events; 28%), injection-related
reaction (1/4 events; 25%), injection-site erythema (72/494
events; 15%), injection-site induration (5/35 events; 14%),
injection-site pain (3/41 events; 7%), injection-site swelling
(1/20 events; 5%), and injection-site pruritus (1/34 events; 3%).

10
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Drisapersen (N = 116)
Placebo (N = 57)

Proportion of Subjects (%)

50

47.4

40
35.3

30

25.9
19.8

20

10

8.6

7.8
2.6

0

35.1

0.0

Very much
improved

1.8

Much
improved

10.5

3.5

0.0

Minimally
improved

No change

Improvement

Minimally
worse

Much worse

1.8

Very much
worse

Worsening
CGI-I at Week 48

Fig. 4. Distribution of the Clinical Global Impression of Improvement scale at week 48.
CGI-I = Clinical Global Impression of Improvement.

Photographs of the injection-site reactions are not shown in this
publication as no permission was obtained from the patients.
Renal AEs were reported more commonly in the drisapersen
(64%) than in the placebo (33%) group, with proteinuria
(34%), hematuria (17%), protein in urine (14%), red blood
cells positivity (11%), and increased cystatin C (11%) most
frequently reported in the drisapersen group. Increases in
α1-microglobulin, serum cystatin C, and KIM-1 in the
drisapersen treatment group were consistent with possible mild
proximal tubule dysfunction and subclinical proteinuria. One
drisapersen-treated subject had a serious AE of moderate
glomerulonephritis.
Hepatic AEs were observed in 6% of drisapersen-treated
subjects, none were considered clinically significant. There
were no clinically relevant differences between treatment
groups in clinical chemistry, hematology, or coagulation values
of potential clinical concern. Platelet count was slightly
reduced in the drisapersen group. However, no AEs related to
decreased thrombocyte count were reported.
4. Discussion
This phase 3 study is one of the largest placebo-controlled
trials in DMD to date. The primary efficacy endpoint was
change from baseline 6MWD over 48 weeks. The 6MWD test
has been adapted to evaluate muscle function and endurance in
neuromuscular disorders, and has been used as the primary
outcome measure in several other international multicenter
clinical trials for DMD [21,25,41]. The pre-planned analysis
of the present phase 3 study demonstrated a small and
insignificant mean treatment benefit in 6MWD of 10.3 meters
over 48 weeks (P = 0.415). This is in contrast with the outcomes
of the 2 randomized, placebo-controlled, phase 2 studies

showing an improvement in mean 6MWD at 24 weeks of 35
meters (P = 0.014) [25] and 27 meters (P = 0.069), respectively.
One possible explanation for this discrepancy is the
increased data variation (pre-specified SD of 55 meters
increased to an actual SD of 87 meters due to less stringent
inclusion/exclusion criteria) in the phase 3 study reducing the
statistical power to detect a treatment difference of 30 meters in
mean change from baseline 6MWD from 90% to 53%. The 87
meters SD for change in 6MWD over 48 weeks is more
consistent with the literature in DMD subjects with wide
variation in baseline 6MWD found in NH studies and clinical
trials [15,21].
A second explanation for the discrepancy is the lack of NH
knowledge at the start of the drisapersen clinical program, with
recent NH studies highlighting the importance of baseline
characteristics, such as age, 6MWD, and the ability to RFF
[9–15]. Subjects with a baseline 6MWD <300 meters are at
greater risk of imminent loss of ambulation with large changes
in 6MWD over 48 weeks being driven by those subjects
who lose ambulation. In contrast subjects with a baseline
6MWD >400 meters change very little over 48 weeks as they
are often in the stage of natural maturation and can present with
a ceiling effect that limits the measurable improvement with a
dystrophin restoration treatment [9–15,39]. In addition, the
inability to RFF is a separate prognostic factor for imminent
loss of ambulation, with 43% of the DMD subjects unable to
perform RFF test losing ambulation within 1 year [39]. Taking
into account these learnings from NH [9–15,39], subjects
included in the phase 3 study had a more severe disease status
at baseline (mean age = 8.2 years, mean 6MWD = 341 meters,
and mean RFF time = 13 seconds) compared with subjects
included in the phase 2 studies (mean age = 7.3 and 7.8 years,
mean 6MWD = 409 meters [in both studies], and mean
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Fig. 5. Mean (±standard error) serum concentration over 48 weeks.
A) Creatine kinase.
B) Lactate dehydrogenase.
* P < 0.05, ** P < 0.01, *** P < 0.001.

RFF time = 5 seconds [in both studies], respectively) [25]
[McDonald et al. Unpublished results]. Furthermore, all
subjects included in the phase 2 studies (except 2 subjects in
DMD114876) were able to perform the RFF test at baseline in
≤7 seconds [25] [McDonald et al. Unpublished results]. In
contrast, due to the lack of a RFF criterion during phase 3 study
enrollment, 13.4% of subjects were unable to perform the RFF
test, predicting a high risk of losing ambulation in the following
year [39]. The 6MWD is not an appropriate measure of

treatment efficacy for subjects at high risk of losing ambulation
prior to the completion of a 48-week clinical trial.
A pre-specified subgroup analysis, taking into account
baseline age (≤7; >7 years), partially addressed this disease
status imbalance issue and showed a greater mean treatment
benefit in favor of drisapersen for the younger (21.5 meters)
than the older population (6.9 meters). A post-hoc MMRM
analysis addressing the imbalance in baseline 6MWD and RFF
time was performed in a subgroup of subjects with a baseline
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Table 2
Incidence of on-treatment adverse events (safety population).

On-treatment AEs
AEs
Drug-related AEs (as determined by
investigator)
Severe AEs
Serious AEs
AEs leading to permanent discontinuation
of study treatment
Any AE of special interest*
Injection-site reaction
Renal effects
Inflammation
Coagulation
Hepatic effects
Low thrombocyte counts
Most common on-treatment AEs (Reported
in ≥5% of subjects in either treatment
group)†
Injection-site erythema
Proteinuria
Injection-site discoloration
Nasopharyngitis
Headache
Vomiting
Pyrexia
Fall
Cough
Injection-site reaction
Diarrhea
Injection-site pain
Hematuria
Protein urine present
Injection-site induration
Injection-site pruritus
Upper respiratory tract infection
Gastroenteritis
Abdominal pain
Red blood cells urine positive
Cystatin C increased
Pain in extremity
Injection-site bruising
Epistaxis
Red blood cells urine
Urine protein/creatinine ratio increased
Rhinitis
Arthralgia
Oropharyngeal pain
Upper abdominal pain
Injection-site hematoma
Injection-site atrophy
Injection-site urticaria
Contusion
Back pain
Influenza
Excoriation
Ligament sprain
Ear pain
Ear infection
Blood fibrinogen decreased

Drisapersen
6 mg/kg/week
(N = 125)

Placebo
(N = 61)

123 (98)
111 (89)

58 (95)
31 (51)

9 (7)
13 (10)
2 (2)

2 (3)
5 (8)
0

114
97
80
33
9
7
0

(91)
(78)
(64)
(26)
(7)
(6)

37
10
20
16
9
0
0

(61)
(16)
(33)
(26)
(15)

62
42
41
38
33
28
27
27
24
24
23
23
21
17
17
17
15
15
14
14
14
11
11
11
11
11
10
10
10
9
9
9
9
8
8
7
7
7
6
4
3

(50)
(34)
(33)
(30)
(26)
(22)
(22)
(22)
(19)
(19)
(18)
(18)
(17)
(14)
(14)
(14)
(12)
(12)
(11)
(11)
(11)
(9)
(9)
(9)
(9)
(9)
(8)
(8)
(8)
(7)
(7)
(7)
(7)
(6)
(6)
(6)
(6)
(6)
(5)
(3)
(2)

4
11
2
25
11
13
15
12
12
1
9
2
5
4
0
0
8
6
7
4
2
12
6
5
4
2
3
1
1
3
2
0
0
7
5
4
3
3
4
5
6

(7)
(18)
(3)
(41)
(18)
(21)
(25)
(20)
(20)
(2)
(15)
(3)
(8)
(7)

(13)
(10)
(11)
(7)
(3)
(20)
(10)
(8)
(7)
(3)
(5)
(2)
(2)
(5)
(3)

(11)
(8)
(7)
(5)
(5)
(7)
(8)
(10)

All values are N (%).
* Defined as AEs resulting from any of the Laboratory Safety Parameter
Stopping criteria for hepatic or renal effects, thrombocyte counts,
inflammation and coagulation abnormalities, and any AEs resulting from
injection-site reactions.
†
Reported in order of descending frequency of total group.
AE = adverse event.

6MWD result between 300 and 400 meters and able to RFF, and
showed a statistically significant treatment benefit of 35.4
meters in favor of drisapersen. This is in line with the fact that
in order for drisapersen to provide benefit, sufficient muscle
tissue needs to be preserved [42]. Less target lower extremity
tissue will become available as ambulation declines due to
progressive replacement of healthy muscle with fat and fibrous
tissue in subjects with increasing age [43,44]. Other endpoints
such as upper limb function may be more appropriate to
measure therapeutic effect in these subjects [45–47]. These
results are also in line with those from the phase 3 clinical trial
with ataluren in 228 nmDMD subjects showing a nonsignificant improvement over placebo of 15 meters in the total
population with a greater statistically significant improvement
over placebo of 47 meters in the subgroup of subjects with a
baseline 6MWD of 300–400 meters (N=99) [48].
A significantly greater percentage of the drisapersen-treated
subjects (30%) showed improvement on the CGI-I scale
compared with placebo-treated subjects (5%). This may suggest
that the CGI-I does not have the same limitations as other
endpoints as it captures the physicians’ global impression of
improvement. In contrast, there were no clinically meaningful
treatment differences between drisapersen and placebo for the
PedsQL neuromuscular module, HUI assessments, and
activities of daily living. This is not surprising as a weak
correlation of the PedsQL physical function scale to variation in
disease was previously reported in DMD [12,33] and the
PedsQL neuromuscular module uses a similar frequency of
difficulty construct. No statistically significant differences were
observed for the pulmonary function tests but data from NH
demonstrate it can be difficult to observe significant treatment
effects after a period of only 48 weeks in ambulatory subjects
and respiratory decline mainly occurs in DMD subjects older
than the population included in the current study [49–51].
Elevated serum CK is used as a diagnostic biomarker for
DMD [52,53] because dystrophin deficiency and associated
muscle fiber damage in DMD result in the release of CK from
the intracellular compartment of muscle fibers into the
circulation. Serum CK concentration, a pre-specified secondary
efficacy endpoint, was statistically significantly reduced in
subjects treated with drisapersen versus placebo as early as 12
weeks and up to 48 weeks (Figure S3). Although in humans CK
is known to decrease with age and stage of the disease, the
observed reduction was irrespective of baseline age and
6MWD. This is in line with placebo-controlled studies in mdx
mice and mdx/utrn (+/-) mice treated with mouse surrogate
exon 23 skipping by 2′-O-methyl-phosphorothioate AONs
[54,55] or by phosphorodiamidate morpholino AONs [56]
demonstrating exon skipping in various muscles and a related
decrease in serum CK. Elevated serum LDH is also considered
a biomarker of muscle disease in DMD subjects [57–60] and
LDH isoform expression is dysregulated in DMD muscles
[58,59]. Post-hoc analysis showed that the reduction in serum
LDH in the drisapersen group reached statistical significance
compared to placebo as early as 12 weeks and up to 48 weeks.
Thus it seems that CK and LDH serve as plausible
pharmacodymanic biomarkers for drisapersen.
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Pharmacokinetic analyses suggest that a steady state
drisapersen plasma concentration was not reached until 36
weeks of treatment whereas optimal drisapersen muscle tissue
and plasma concentration were not reached until 36 or 48 weeks
of treatment, respectively. This suggests that, given the long
half-life of drisapersen, maximal response would not have been
reached until the end of the phase 3 study. Furthermore in a
more impaired DMD population, accumulation of adipose and
fibrous tissue limits the amount of muscle that drisapersen can
target. In contrast, the DMD114117 study, which showed a
statistically significant treatment effect on the pre-specified
primary endpoint, used a 3-week loading dose of drisapersen
and the study enrolled a younger population of DMD subjects
with a higher baseline 6MWD (mean 409 meters) and relatively
preserved RFF (mean 5 seconds).
Sc administration of drisapersen was generally tolerated and
the safety profile was consistent with previous studies [25,61].
The most common AEs were injection-site reactions and renal
events (mainly subclinical proteinuria due to competitive
binding of drisapersen, therefore leading to leakage of
proteins). One drisapersen-treated subject had a serious AE of
glomerulonephritis and discontinued from the study. No deaths
occurred during the study and the incidence of serious AEs
leading to withdrawal was low (1.6%) in the drisapersen group.
It is known from literature that sc administration of AONs
results in the occurrence of local skin reactions originating
around the injection-site and manifests itself as erythema,
induration, itching, discomfort, pain, or more severely as
ulceration or necrosis [62]. Although none of the injection-site
reactions were reported as a serious AE in the current study,
16% remained unresolved upon the end of the study. It has been
reported in literature that these persistent injection-site
reactions could potentially evolve further to sclerosis,
calcification, and ulcerations over time [62]. Therefore, ongoing
monitoring and management are required. Any new events
occurring after 2015 were to be reported to the sponsor. As
described for many other AONs [62], the evolving injection-site
reactions were one of the reasons that drisapersen did not reach
approval.
In summary, compared with the phase 2 studies [25]
[McDonald et al. Unpublished results], the current phase 3
study demonstrated a smaller but positive trend toward
improvement in 6MWD versus placebo for the pre-specified
analysis. Post-hoc analysis based on the evolving understanding
of the NH of DMD in a subgroup of subjects with a baseline
6MWD between 300 and 400 meters and who were able to RFF
showed a greater mean treatment benefit of drisapersen over
placebo after 48 weeks of follow-up, with a comparable 6MWD
treatment difference observed as in the phase 2 studies.
Furthermore, pre-specified subgroup analysis showed a greater
treatment benefit of drisapersen in the younger than in the older
population, reinforcing the need to treat early to maintain
functional ambulatory capacity. Even though these results were
promising and subjects treated with drisapersen have
maintained stable ambulatory function in an extension study for
3.4 years [26], further clinical development of drisapersen has
been terminated by the study sponsor.
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Selecting a well-defined, less variable DMD population
randomized for prognostic factors (6MWD, age, and RFF time)
and longer trial duration may aid in showing a clearer
statistically significant treatment effect in future trials with
AONs.
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